Analisi etica in un processo di HTA della combinazione fissa “olmesartan medoximil+amlodipina” nel trattamento dell’ipertensione arteriosa

Translated title of the contribution: [Autom. eng. transl.] Ethical analysis in an HTA process of the fixed combination "olmesartan medoximil + amlodipine" in the treatment of high blood pressure

Research output: Contribution to journalArticlepeer-review

Abstract

[Autom. eng. transl.] The evidence that fixed combinations favor more persistent treatment than impromptu ones has led to focusing attention on these associations, which can also be a mandatory choice where monotherapy is no longer sufficient. Hence the development of the fixed combination of an angiotensin II receptor antagonist and a calcium channel blocker, which is the subject of this ethical evaluation in HTA (Health Technology Assessment).
Translated title of the contribution[Autom. eng. transl.] Ethical analysis in an HTA process of the fixed combination "olmesartan medoximil + amlodipine" in the treatment of high blood pressure
Original languageItalian
Pages (from-to)69-74
Number of pages6
JournalItalian Journal of Public Health
Volume3
Publication statusPublished - 2014

Keywords

  • Hta
  • etica
  • ipertensione arteriosa
  • olmesartan medoximil+amlodipina

Fingerprint

Dive into the research topics of '[Autom. eng. transl.] Ethical analysis in an HTA process of the fixed combination "olmesartan medoximil + amlodipine" in the treatment of high blood pressure'. Together they form a unique fingerprint.

Cite this